## Exhibit D

```
1
                     UNITED STATES DISTRICT COURT
                      DISTRICT OF NEW JERSEY
 2
 3
 4
    UNITED THERAPEUTICS CORPORATION,
 5
         Vs.
                                          CIVIL NO.
 6
                                         12-1617 (PGS)
    SANDOZ, INC.,
                                         13-316
 7
                    DEFENDANT
 8
 9
                              MAY 8, 2014
10
                              CLARKSON S. FISHER COURTHOUSE
                              402 EAST STATE STREET
11
                              TRENTON, NEW JERSEY 08608
12
13
                       THE HONORABLE PETER G. SHERIDAN
    BEFORE:
14
                       U.S. DISTRICT COURT JUDGE
                       DISTRICT OF NEW JERSEY
15
16
17
    TRIAL - DAY 4
18
19
20
21
22
                         Certified as true and correct as required
23
                         by Title 28, U.S.C. Section 753
                         /S/ Francis J. Gable
24
                         FRANCIS J. GABLE, C.S.R., R.M.R.
                         OFFICIAL U.S. REPORTER
25
                         (856) 889-4761
```



## Zaccardelli - Cross - Steindler

- 1 so that you don't get them. Whether they're treatable or not
- 2 I think depends on many factors, including the type of
- 3 organism and the patient's health status.
- 4 Q. Could you turn to PTX-500, please.
- **5** A. Yes.
  - 6 Q. I believe you testified this is the AET testing that you
  - 7 had conducted with Remodulin and Sterile Diluent for Flolan;
  - 8 is that correct?
  - 9 A. It's the -- yes, the report contains that data.
- 13:14 **10** Q. And that data is also contained in the '007 patent;
  - **11** right?
  - 12 A. Yes. Some of it at least is, yes.
  - 13 Q. And it's also reflected in the article that you authored;
  - 14 right?
- 13:14 **15** A. Yes, at least some of it is.
  - 16 Q. Well, let's go to PTX-576. It's a version of the
  - 17 Remodulin label, I don't think you'll find it in your binder.
  - 18 A. I don't think I have it.
  - 19 Q. You're familiar with the Remodulin label; correct?
- 33:15 **20** A. Yes, I'm familiar with it.
  - 21 Q. So, let's go to Section 11. If you will. Scroll down.
  - 22 And just blow up that first portion.
  - 23 Now, Remodulin is comprised of a number of different
  - 24 products -- ingredients; right?
- 03:15 **25** A. Yes.



## Zaccardelli - Cross - Steindler

- 1 Q. So it's got sodium chloride in it, metacresol, sodium
- 2 citrate, and water; right?
- 3 A. Yes.
- 4 Q. Of those ingredients metacresol is a preservative and
- - 6 A. Yes, metacresol is in the formulation to serve those
  - 7 purposes.
  - 8 Q. Let me just be clear that I understand your answer.
  - 9 Metacresol is an antimicrobial agent; correct?
- 16 10 A. I -- I can say that it's in the formulation in order to
  - 11 achieve antimicrobial effectiveness testing by the USP.
  - 12 Q. You're not able to say whether metacresol in your product
  - 13 is an antimicrobial agent?
  - 14 A. I'm not a specific chemist or microbiologist. I can say
- 13:16 **15** it's in there in order to achieve the antimicrobial
  - 16 effectiveness test; all attributes I can't -- I can't attest
  - **17** to.
  - 18 Q. Let's go to PTX-912, please. This one is in your binder.
  - **19** A. Yes.
- 33:17 **20** Q. And you recall that this is the article by Rich, et al,
  - 21 that you talked about on your direct examination; right?
  - 22 A. Correct.
  - 23 Q. Could you turn to the page Bate stamp 1162350.
  - **24** A. Yes, I have it.
- 33:18 **25** Q. Bear with me for a moment.

